Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%

MT Newswires Live

Aug 04, 2025

Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.

Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.

The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.

Its shares fell 14% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556877445"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556877445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556877445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 12:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556877445","market":"sh","top_or_hot":-1,"title":"Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-04 12:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2556877445","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556877445","pubTimestamp":1754283189,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chimeric Therapeutics  said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","CHM.AU":"CHIMERIC THERAPEUTICS LTD","BK4539":"次新股","BK4139":"生物科技","BK7067":"生物科技"},"translate_title":"Chimeric Therapeutics称肿瘤候选治疗研究进展至第二剂量水平，股价下跌14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHM.AU":0.9,"LENZ":1},"content_text":"Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}